

## Underactive bladder - an underestimated entity

Spinu Arsenie Dan<sup>1,2</sup>, Ovidiu Gabriel Bratu<sup>1,2,3</sup>, Dragos Radu Marcu<sup>1,2</sup>, Adina Elena Stanciu<sup>4</sup>, Florentina Gherghiceanu<sup>1</sup>, Florentina Ionita-Radu<sup>5</sup>, Simona Bungau<sup>6</sup>, Ana Maria Alexandra Stanescu<sup>1</sup>, Dan Mischianu<sup>1,2,3</sup>

<sup>1</sup>CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, BUCHAREST, ROMANIA

<sup>2</sup>UNIVERSITY EMERGENCY CENTRAL MILITARY HOSPITAL, DEPARTMENT OF UROLOGY, BUCHAREST, ROMANIA

<sup>3</sup>ACADEMY OF ROMANIAN SCIENTISTS, BUCHAREST, ROMANIA

<sup>4</sup>INSTITUTE OF ONCOLOGY BUCHAREST, DEPARTMENT OF CARCINOGENESIS AND MOLECULAR BIOLOGY, BUCHAREST, ROMANIA

<sup>5</sup>UNIVERSITY EMERGENCY CENTRAL MILITARY HOSPITAL, DEPARTMENT OF GASTROENTEROLOGY, BUCHAREST, ROMANIA

<sup>6</sup>UNIVERSITY OF MEDICINE AND PHARMACY, ORADEA, ROMANIA

### ABSTRACT



**Introduction.** The concept of underactive bladder is relatively new. Currently there is no generally accepted definition of this pathology. Diagnosis depends on urodynamic findings, and symptoms are usually rare and intricately with the symptoms of other urinary pathology.

**Materials and methods.** This review examines the current literature on underactive bladder regarding pathology, definition, diagnosis, current guidelines, and any further potential medical developments.

**Conclusions.** Underactive bladder is a poorly understood pathologic condition. Only since 2002 has there been any consensus regarding the definition. The diagnosis relies only on urodynamics; clinical diagnosis is a challenge even for a consultant; and treatment does not seem to alleviate much of the suffering. This disease remains unrecognized and undertreated. More research is needed to identify less invasive diagnosis tools and treatment for this pathology.

**Category:** Review

**Received:** October 12, 2019

**Accepted:** February 16, 2020

**Keywords:**

underactive bladder, detrusor underactivity, diagnosis, treatment

**\*Corresponding author:**

Dragos Radu Marcu, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  
E-mail: [marcuradudragos@yahoo.com](mailto:marcuradudragos@yahoo.com)

## Introduction

In 2002, the International Continence Society reviewed the existing data and arrived at a definition for underactive bladder: 'a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or failure to achieve complete bladder emptying within a normal time span'. However, the definition for this pathology had been evolving over some time. For instance, in 1996 the International Continence Society defined underactive bladder as failure to induce emptying of at least half of the bladder with involuntary recurrent contractions without the evidence of straining, urethral obstruction, and detrusor sphincter dyssynergia. After the 2002 definition was presented (above), in 2010, the society revised the definition as a decrease in detrusor contraction and/or shortening of the contraction time, resulting in an incomplete and/or prolongation of the bladder emptying within the normal time frame [1].

For years, this condition has been overlooked. Its counterpart, the overactive bladder, had received much greater research interest, perhaps due to its more intrusive symptomatology.

The pathology has borne many names: impaired detrusor contractility, bladder failure, bladder decompensation, hypotonic bladder, detrusor areflexia, and detrusor failure and detrusor underactivity, although some authors suggest the last one represents its own category, a point subject to debate [2-4].

The diagnosis for this disease relies mostly on urodynamic findings. The prevalence increases with age and is typically greater in men. Prevalence ranges from 9 to 28% in men under 50 years old and more than 48% in those over 70 years old. In women, the incidence ranges from 12 to 45% [5,6]. Yet, no consensus exists for threshold urodynamic values for disease categorization. Although various papers have proposed different thresholds, no widely accepted guidelines currently exist.

## Discussions

A comprehensive search of PubMed, Scopus, and other databases was conducted using key words like "underactive bladder, detrusor underactivity". Review articles were selected. Several older papers were included for citations and historic interest. Prevalence, etiology, diagnosis, and treatment possibilities were searched. The purpose of this paper is to highlight the cardinal aspects of this pathology.

### *Etiology*

The etiology of this disease is wide and may be separated into five broad categories: idiopathic - young patients with no apparent affections; myogenic - any subvesical obstacle and diabetes, autonomic diabetic neuropathy [7], Parkinson disease, different types of sclerosis, disc hernias [8]; spinal cord injury, spinal dysraphism and stenosis; infectious - HIV, herpes zoster, herpes simplex and neurosyphilis; and last iatrogenic - pelvic surgery, radical prostatectomy, radical hysterectomy [9-11]. In diabetes, chronic hyperglycemic status induces a series of tissues and organ damages. Microvascular involvements in diabetic patients are more common; retinopathy, neuropathy, and chronic kidney disease are the main complications in diabetes. Autonomic diabetic neuropathy develops a series of urological sequelae like erectile dysfunction, retrograde ejaculation, and diabetic bladder dysfunction. More than half of diabetic patients develop diabetic bladder dysfunction, and clinical signs are described as a triad, including a bladder sensation decrease, bladder capacity increase, and imperfect detrusor contractility [12]. Moreover, modifications appear at the urothelium level: decreases in E-cadherin levels and muscarinic receptor 2 and 3 expressions seem to be lower in patients with underactive bladder [13].

The most frequent cause is the neurogenic one; actually disruption of the efferent neural pathways seems to be one of the most frequent types of neural damage. From the pathologic point of view, changes in the ultrastructure of myocytes and gap junctions inhibit detrusor contraction and deposition of collagen between muscle bundle [14,15].

### *Diagnosis*

A proper diagnosis requires some sort of invasive method, specifically urodynamic assessment. The diagnosis can be difficult because of the overlapping symptoms with other pathologies like bladder outlet obstruction, benign prostatic hyperplasia, and overactive bladder. The condition can be deceptive, sometimes presenting with both voiding and storage symptoms. Urgency (63.3%), weak stream (61%), straining to void (57%), and nocturia (48.1%) may all be present, making it difficult to differentiate from other related diseases. In one paper, the authors stressed the importance of pressure flow

investigations, as 12,7% of patients with underactive bladder were mistakenly treated with anticholinergics [16].

Patients presenting with overactive bladder and receiving some form of treatment may change at some point in their pathology, and an overstimulated bladder can become hypotonic. Moreover, overactive bladder, bladder outlet obstruction, and underactive bladder can coexist, making it difficult to treat. In diabetes, the first process is bladder hypertrophy with increased contractility, which leads to polyuria. The second stage is linked with hyperglycemic status which leads to the development of toxic metabolites which affect normal bladder function and promote the detrusor muscle dysfunction. In the end stage, both mechanisms will lead to an atonic bladder. Chronic hyperglycemic status induces chronic oxidative stress and releases reactive oxygen species. This partially explains the pathophysiology of diabetic bladder dysfunction, especially damaging neuronal fibers, smooth muscles, and altering urothelial function [17-19]. Recognized clinical risk factors include age, indwelling urinary catheter, diabetes, history of urinary retention, and neurologic conditions [20-26].

Still, many useful tools besides urodynamics are available to help recognize this condition. A thorough anamnesis from the patient is mandatory in order to identify any risk factors for this pathology. A voiding diary is useful to determine the severity of the symptoms; a neurological exam should also be conducted. The Schaefer nomogram or a comparable tool may be used to measure obstruction and detrusor contractility [27].

Efforts are ongoing to identify and standardize different clinical tools that can differentiate this pathology from other lower urinary tract diseases. For example, Gammie et al. compared normal patients with underactive bladder patients: Men with underactive bladder (DU) had statistically higher occurrence of decreased/interrupted stream (56% versus 30%), hesitancy (51% versus 26%), feeling of incomplete bladder emptying (36% versus 22%), palpable bladder (14% versus 1.1%), and absent/decreased sensation (13% versus 3.0%). Women with DU had higher rates of decreased/interrupted stream (29% versus 4.0%), hesitancy (28% versus 9.1%), feeling of incomplete emptying (28% versus 20%), palpable bladder (3.3% versus 1.5%), absent/decreased sensation (4.3% versus 0.8%), enuresis (12% versus 8.4%), and impaired mobility (13% versus 2.8%). On the other hand, when compared to those with bladder outlet obstruction, men with underactive bladder reported higher rates of sexual dysfunction, stress incontinence, palpable bladder, enuresis, training to void, and absence of sensation. Better results included better stream, hesitancy, and urgency [28].

Overlapping their findings with urodynamics should be the next logical step. The symptomatology of this disease

is so undefined that there is need for discrimination tools for all the signs and symptoms [29,30]. For instance, multiple sclerosis can manifest with obstructive symptoms predominantly or diabetes with reduced sensation of bladder fullness due to the diabetic neuropathy.

### *Urodynamics*

Currently, pressure flow urodynamic testing is the only accepted and reliable tool for diagnosing underactive bladder. Even this investigation is controversial, for example, with respect to the maximum normal value of voiding pressure. Moreover, there is no accepted urodynamic definition values for underactive bladder. Several universally accepted parameters can narrow down the list, including a bladder contractility index (BCI) of  $<100$  ( $P_{detQ_{max}} + 5Q_{max}$ ), detrusor pressure at max flow ( $P_{detQ_{max}}$ ) of  $<30\text{mmH}_2\text{O}$  and a maximum flow rate ( $Q_{max}$ ) of  $<12\text{ml/sec}$ , and a bladder outlet obstruction index (BOOI) ( $P_{detQ_{max}} - 2Q_{max}$ ) of  $<20$  and a  $Q_{max}$  of  $<12\text{ml/sec}$  [31,32]. Others use the Watts factor, which is an estimate of the power per unit area of the bladder surface that is generated by the detrusor. This measure is not

affected by bladder volume and is therefore not influenced by increased outlet resistance. Unfortunately there are no standards for its use, and its complexity makes it a challenge to use [33,34].

Projected isovolumetric pressure - PIP and its derivatives: bladder contractility index - BCI and detrusor coefficient - DECO have the advantage of being much easier to use; however, they may overestimate PIP and have less test-retest reliability than measuring isovolumetric pressures directly [35].

Another useful urodynamic investigation is the mechanical occlusion of flow. This test can be controlled by the patient or if needed by the doctor by compressing the urethra. This test tends to underestimate pressure by 20 cc H<sub>2</sub>O.

Unfortunately, its greatest disadvantage is that it cannot be applied to patients with sphincter weakness or to elderly patients. Compression of the urethra can also be a rather painful procedure. We also mention two other measures, detrusor contraction speed or detrusor velocity, both of which have limited use in general practice [36].

**Table 1.** A schematic representation of most common urodynamic tests [37].

<b><u>Methods</u></b>	<b><u>Advantages</u></b>	<b><u>Disadvantages</u></b>
Bladder contractility index BCI = $P_{detQ_{max}} + 5Q_{max}$ DU = BCI $<100$	Easy to use	Not validated in women; cannot measure contraction sustainability
Watts Factor WF = $[(p_{det} + a)(v_{det} + b) - ab]/2\pi$	Not affected by bladder outlet obstruction (BOO); measures bladder power	Complex formula; impractical to use clinically; cannot measure contraction sustainability; diagnostic thresholds not established
Mechanical flow occlusion Stop test Continuous occlusion test	Measures isovolumetric contraction strength	Cannot be done in those with sphincter weakness or elderly; painful and impractical
Maastricht-Hannover nomogram DU $\leq 25$ th percentile	Quantifies relationship between detrusor contractility and BOO	Not validated in women
Urodynamic cut-offs	Easy to use	No accepted normal ranges

### ***Treatment options***

Treatment can be classified as behavioral, medical, surgical, and experimental/promising. Behavioral treatment includes time voiding and double voiding, which can reduce the urinary stasis and its subsequent sequelae. Intermittent catheterization or catheterization is one of the last solutions and greatly affects the life quality of the patients and increases the risk of other complications such as infection, urethral stricture, urethroragia, and so on.

Medical treatment, on the other hand, has unfortunately shown little or no success. One of the most used classes of substances are the parasympathomimetics with their main representative bethanechol chloride. This substance is a parasympathomimetic choline carbamate that selectively stimulates muscarinic receptors with little effect on nicotinic receptors. Distigmine bromide, another parasympathomimetic, is an acetylcholinesterase inhibitor that inhibits the acetylcholinesterase enzyme from deactivating acetylcholine, thereby increasing both the

level and duration of action of acetylcholine in neuromuscular junctions. Both of them have been used for many years and both have produced conflicting results.

Barendrecht et al in their review concluded that there is no evidence for using these drugs in the treatment of underactive bladder, taking into account the potential side effects which include nausea, vomiting, diarrhea, gastrointestinal cramps, bronchospasms, salivation, sweating, headache, flushing, visual accommodation defect, and the rare but potentially lethal complication of cardiac arrest. Moreover, this medication showed improvement over the control group only in three of 10 studies, the remaining seven showing no benefit, and one even worsening the symptomatology [38,39].

Alpha blockers represent a widespread medication for bladder outlet obstruction, currently recommended in the European guidelines as first line therapy for this disease. Their effect lies more in the bladder neck where the concentration of alpha receptors is the highest as compared to the overall bladder [40].

The use of cholinesterase inhibitors distigmine, pyridostigmine, and neostigmine are efficient neurologic medication and have been supported in the treatment of underactive bladder. For example, Sugaya et al, in relatively recent paper testing distigmine associated with alpha blockers, noticed an improvement in the IPSS score, quality of life scores, and post voiding residue. Still this type of medication has several annoying side effects, including frequent defecation, fecal incontinence, diarrhea, frequent urination, and decrease in physical condition [41].

Prostaglandin E2, a substance derived from cardiac medication, increases detrusor contraction and relaxes the urethra. It is administered intravesically but has no recommendations for sole use. Several studies have combined PGE2 with oral bethanecol with promising results, but no general recommendations have as yet followed [42-44].

Acotiamide is an oral agent that regulates the motility of the upper gastrointestinal tract in patients with abdominal symptoms related to hypomotility and delayed gastric emptying. 100 mg dose t.i.d. seems effective for patients with underactive bladder. Sugimoto et al have emphasized this substance as an alternative to distigmine [45].

Surgical treatment consists of a wide variety of procedures and nerve stimulation techniques ranging from sacral electrical stimulation, injections into the external sphincter, trans-urethro resection of the prostate, reduction cystoplasty, latissimus dorsi detrusor myoplasty, transurethral incision of the bladder neck in women, and bladder diverticulectomy.

Some of them, like TUR-P or incision of the bladder neck in women and injections of botulinum toxin into the external sphincter, are surgical procedures meant to relieve

the obstruction. Others like reduction cystoplasty, latissimus dorsi myoplasty, and bladder diverticulectomy have the purpose of eliminating the complications of this disease, the aging of the bladder [45,46].

## Conclusions

Underactive bladder or any of its synonyms is a poorly understood disease with a very difficult diagnosis. Clinical diagnosis has limited value and positive diagnosis is based only on urodynamics. Even bladder pressure studies have limitations, as normative values are missing. No standardized efficient treatment exists, so therapy tends to be tailored, as some drugs work on some patients, some do not. Medical approach has limited use, surgery can relieve the pressure only for a short time like TUR-P, or it deals with disease complications. Sacral neuromodulation seems for now to be the only real efficient treatment. Future therapies like gene therapy or stem cells therapy show great promise but need to be supported by well-designed empirical studies.

## Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

## Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

## References

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Am J Obstet Gynecol.* 2002;187(1):116–26.
2. Madjar S, Appell RA. Impaired detrusor contractility: anything new? *Curr Urol Rep.* 2002;3(5):373–7.
3. Alexander S, Rowan D. Treatment of patients with hypotonic bladder by radio-implant. *Br J Surg.* 1972;59(4):302.
4. Kirby RS, Fowler C, Gilpin SA, et al. Non-obstructive detrusor failure. A urodynamic, electromyographic, neurohistochemical and autonomic study. *Br J Urol.* 1983;55(6):652–659. doi:10.1111/j.1464-410x.1983.tb03398.x.
5. Smith PP, Hurtado EA, Appell RA. Post hoc interpretation of urodynamic evaluation is

- qualitatively different than interpretation at the time of urodynamic study. *Neurourol Urodyn.* 2009;28(8):998-1002.
6. Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V, et al. Detrusor underactivity and the underactive bladder: A new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. *Eur Urol.* 2014;65(2):389-98.
  7. Diaconu C. Treatment of diabetes in patients with heart failure. The 3rd International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications – Diabetes mellitus in Internal Medicine, INTERDIAB 2017 Proceedings, pp. 170-177. Editura Niculescu. Editors Serafinceanu C, Negoita O, Elian V.
  8. Diaconu C. Midaortic syndrome in a young man. *Cor et Vasa* 2017; 59: e171 - e173. doi: 10.106/j.crvasa.2016.04.007.
  9. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn.* 2010;29(1):4-20.
  10. Marcu D, Spinu D, Mischianu D, Socea B, Oprea I, Bratu O. Oncological follow-up after radical prostatectomy. *Rom J Mil Med.* 2017;120(3):39-42.
  11. Popescu R, Bratu O, Spinu D, Marcu D, Farcas C, Dinu M, Mischianu D. Neuroendocrine differentiation in prostate cancer –a review. *Rom J Mil Med.* 2015;118(3):16-19.
  12. Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT and Chacko S. Diabetic Bladder Dysfunction: current translational knowledge. *J Urol.* 2009;182(6):18-26.
  13. Jiang YH, Kuo HC. Urothelial barrier deficits, suburothelial inflammation and altered sensory protein expression in detrusor underactivity. *J Urol.* 2017;197(1):197-203.
  14. Brierly RD, Hindley RG, McLarty E, Harding DM, Thomas PJ. A prospective controlled quantitative study of ultrastructural changes in the underactive detrusor. *J Urol.* 2003;169(4):1374–8.
  15. Levin RM, Longhurst PA, Barasha B, Mcguire EJ, Elbadawi AJ, Wein AJ. Studies on experimental bladder outlet obstruction in the cat: long-term functional effects. *J Urol.* 1992;148(3):939–43.
  16. Hoag N, Gani J. Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment. *Int Neurourol J.* 2015;19(4):185-9.
  17. Deli G, Bosnyak E, Pusch G, Komoly S and Feher G. Diabetic neuropathies: Diagnosis and management. *Neuroendocrinology* 2013;98(4):267–280.
  18. Wittig L, Carlson KV, Andrews MJ, Crump RT, Baverstock RJ. Diabetic bladder dysfunction: A review, *Urology* 2018. doi: <https://doi.org/10.1016/j.urology.2018.10.010>
  19. Pantea-Stoian A, Stefanca F, Stefanca S, et al. The correlation between HbA1c and the metabolic syndrome in chronic renal disease in patients with diabetes. Conference: 1st International Conference on Interdisciplinary Management of Diabetes Mellitus and its Complications (INTERDIAB) Location: Bucharest, ROMANIA Date: MAR 26-28, 2015 Sponsor(s): Assoc Renal Metab & Nutrit Studies; Romanian Soc Diabet Nutr & Metab Dis; Natl Inst Diabet, Nutr & Metab Dis; AstraZeneca Diabet; MSD Diabet; Novo Nordisk; Sanofi; Lilly Diabet; Berlin Chemie Menarini; Accu Chek; Boehringer Ingelheim; Pfizer; Fresenius Med Care; Amgen; Servier; Vifor Pharma; Merck Serono; Merck; Chimimportexport Plurimex S R L Interdisciplinary Approaches In Diabetic Chronic Kidney Disease, 2015, pp. 262-270.
  20. Abarbanel J, Marcus E-L. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. *Urology.* 2007; 69(3):436–440.
  21. Massey JA, Abrams PH. Obstructed voiding in the female. *Br J Urol.* 1988;61(1):36–39.
  22. Manea M, Marcu D, Pantea Stoian A, et al. Heart failure with preserved ejection fraction and atrial fibrillation: a review. *Rev Chim (Bucharest).* 2018;69(11):4180-4184.
  23. Groutz A, Gordon D, Lessing JB, et al. Prevalence and characteristics of voiding difficulties in women: are subjective symptoms substantiated by objective urodynamic data? *Urology.* 1999;54(2):268–272.
  24. Valentini FA, Robain G, Marti BG. Urodynamics in women from menopause to oldest age: what motive? What diagnosis? *Int Braz J Urol Off J Braz Soc Urol.* 2011;37(1):100–107.
  25. Valente S, DuBeau C, Chancellor D, et al. Epidemiology and demographics of the underactive bladder: a cross-sectional survey. *Int Urol Nephrol.* 2014;46(Suppl 1):S7–S10.
  26. Jeong SJ, Kim HJ, Lee YJ, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. *Korean J Urol.* 2012;53(5):342–348.
  27. Schaefer W. Basic principles and clinical application of advanced analysis of bladder voiding function. *Urol Clin N Am.* 1990;17(3):553–66.
  28. Gammie A, Kaper M, Dorrepaal C, et al. Signs and Symptoms of Detrusor Underactivity: An Analysis of Clinical Presentation and Urodynamic Tests From

- a Large Group of Patients Undergoing Pressure Flow Studies. *Eur Urol.* 2016;69(2):361–9.
29. Balaceanu A, Mateescu D, Diaconu C, Sarsan A. Primary malignant fibrous histiocytoma of the right ventricle: a case report and review of the literature. *Journal of Ultrasound in Medicine.* 2010;29(4):655–658.
30. Laslo C, Pantea Stoian A, Socea B, et al. New oral anticoagulants and their reversal agents. *Journal of Mind and Medical Sciences* 2018;5(2):195–201.
31. Abrams P. Bladder Outlet Obstruction Index, Bladder Contractility Index and Bladder Voiding Efficiency: Three Simple Indices to Define Bladder Voiding Function. *BJU Int.* 1999;84(1):14–15.
32. Lim C, Abrams P. The Abrams-Griffiths Nomogram. *World J Urol.* 1995;13(1):34–39.
33. Griffiths DJ. Assessment of Detrusor Contraction Strength or Contractility. *Neurol Urodyn.* 1991;10(1):1–18.
34. Lecamwasam HS, Yalla SV, Cravalho EG, et al. The maximum watts factor as a measure of detrusor contractility independent of outlet resistance. *Neurol Urodyn.* 1998;17(6):621–35.
35. Tan TL, Bergmann MA, Griffiths D, et al. Which stop test is best? Measuring detrusor contractility in older females. *J Urol.* 2003;169(3):1023–7.
36. Sullivan MP, DuBeau CE, Resnick NM, et al. Continuous occlusion test to determine detrusor contractile performance. *J Urol.* 1995;154(5):1834–40.
37. Gani J, Hennessey D. The underactive bladder: diagnosis and surgical treatment options. *Transl Androl Urol.* 2017;6(Suppl 2):S186–S195.
38. Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? *BJU Int.* 2007;99(4):749–52.
39. Ardeleanu V, Toma A, Pafili K, Papanas N, Motofei I, Diaconu CC, Rizzo M, Stoian AP. Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review. *Medicina* 2020;56(1), 25. <https://doi.org/10.3390/medicina56010025>
40. Blok B, Pannek J, Castro-Diaz D, Del Popolo G, Groen J, Hamid R, et al. EAU Guidelines on Neuro-Urology. © European Association of Urology (EAU), 2018.
41. Sugaya K, Kadekawa K, Onaga T, Ashitomi K, Mukouyama H, Nakasone K, et al. Effect of distigmine at 5 mg daily in patients with detrusor underactivity. *Nihon Hinyokika Gakkai Zasshi.* 2014;105(1):10–6.
42. Hindley RG, Brierly RD, Thomas PJ. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. *BJU Int* 2004;93:89–92.
43. Bartos D, Diaconu C, Badila E, Daraban AM. Old and new in lipid lowering therapy: focus on the emerging drugs. *Farmacia* 2014;62(5):811–823.
44. Motofei IG, Rowland DL, Baconi DL, Georgescu SR, Paunica S, Constantin VD, Balalau D, Paunica I, Balalau C, Baston C, Sinescu I. Therapeutic considerations related to finasteride administration in male androgenic alopecia and benign prostatic hyperplasia. *Farmacia.* 2017; 65(5): 660–666
45. Abdel-Daim M.M., El-Tawil O.S., Bungau S.G., Atanasov A.G., Applications of Antioxidants in Metabolic Disorders and Degenerative Diseases: Mechanistic Approach, Oxidative Medicine and Cellular Longevity, vol. 2019, ID 4179676, 3 pages, 2019. <https://doi.org/10.1155/2019/4179676>
46. Sugimoto K, Akiyama T, Shimizu N, Matsumura N, Hayashi T, Nishioka T, et al. A pilot study of acotiamide hydrochloride hydrate in patients with detrusor underactivity. *Res Rep Urol* 2015;7:81–3.